The rationale for assessing the potential of BGP-15 here, in a model of early-stage diabetic cardiomyopathy, was related to earlier reports of the molecule, as BGP-15 exhibited insulin-sensitizing properties, protective effects against muscular dystrophy, cardiotoxicity, heart failure and atrial fibrillation [15,16,17]. This evidence concerns the gene INS and heart failure.